英格兰肺胸病死亡率趋势 (2004-2023):基于人口的观察性研究
Xiaomin Zhong1, Eva J A Morris1, Raph Goldacre1
1Applied Health Research Unit, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
The Lancet regional health. Europe
|March 12, 2026
概括
在英格兰,自发性肺胸病死亡率下降到2019年,然后上升,而COVID-19影响了2021年的死亡率. 低估了肺胸部的价值
科学领域:
- 公共卫生 公共卫生
- 呼吸系统医学 呼吸系统医学
- 流行病学 流行病学
背景情况:
- 监测肺胸病死亡率对于了解疾病负担和指导医疗保健规划至关重要.
- 本研究重点关注2004年至2023年英格兰自发性肺胸炎 (SP) 死亡率趋势.
研究的目的:
- 在20年的时间里分析英格兰自发性肺胸病死亡率趋势.
- 确定死亡率的变化和导致因素,包括COVID-19的影响.
主要方法:
- 基于人口的观察性研究,使用链接的国家死亡登记和医院病例统计数据.
- 通过死亡证明上的任何提及来定义与SP相关的死亡率;根据潜在原因来确定SP特异性.
- 原发性和二次性SP的修改定义包括患有或没有慢性肺病的患者.
主要成果:
- 总共有6,442个与SP相关的死亡被确定;5,055是住院死亡.
- 与SP相关的死亡率在2004-2019年期间下降,但在2019年后增加,在2021年达到顶峰.
- 2021年死亡率的激增主要与COVID有关;非COVID死亡率保持稳定.
结论:
- 随着COVID-19的流行,SP死亡率的下降趋势被打破了.
- 仅仅依靠潜在的死亡原因低估了肺胸部对死亡率的贡献.
- 肺胸炎是导致死亡的重要原因,特别是在65岁以上,有或没有肺部疾病的人群中.
更多相关视频
相关概念视频
Pneumothorax-II
1.3K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
1.3K
Pneumothorax-I
1.9K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
1.9K
Pneumonia III: Complications and Assessment
1.1K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.1K
Pneumonia I: Introduction
1.2K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.2K
Pneumonia IV: Management
992
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
992
Flail Chest-II
820
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
820


